Rapid Novor Inc is a Waterloo, Ontario, Canada based biotech company dedicated to developing unparalleled analytical technologies to significantly improve early stage drug research and development in the bio-pharmaceutical sector. Specializing in the field of mass spectrometry-based proteomics, the Novor team provides antibody protein sequencing solutions to researchers in pharmaceutical companies, contract research organizations and academic research institutions around the globe. We efficiently deliver accurate, comprehensive results, allowing researchers to rapidly make decisions that move their science forward.
Location: Canada, Ontario, Kitchener
Employees: 51-200
Phone: +1 855-899-9990
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | China Grow... | en.cgcvc.c... |
Mentions in press and media 8
| Date | Title | Description |
| 14.05.2024 | Rapid Novor Teams Up with PMCC to Evaluate EasyM™ for Multiple Myeloma Minimal Residual Disease Monitoring | A clinical lab technician analyzing EasyM samples on mass spectrometer. A Canadian Multiple Myeloma (MM) clinical trial sponsored by Rapid Novor, has enrolled its first patient. This is the first Canadian prospective clinical study aiming t... |
| 13.03.2024 | Rapid Novor and MAbSilico Partner for World's First AI-Guided Epitope Mapping Service for Antibodies | Scientist working on the HDX-MS platform utilizing Waters Cyclic IMS MS technology for advanced antibody epitope mapping analysis Rapid Novor and MAbSilico partner to provide the world's first comprehensive AI-guided epitope mapping service... |
| 05.06.2023 | Breakthrough: Sequencing Functional Antibody Proteins Directly from Human Blood | Adjusting a mass spectrometer for protein sequencing The REpAb® technology is well-positioned to fit into any therapeutic antibody discovery pipeline. KITCHENER, Ontario (PRWEB) June 05, 2023 Rapid Novor Inc., the world’s leader in mass spe... |
| 16.03.2023 | Rapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US | Abir Khaled, Multiple Myeloma Senior Research Scientist at Rapid Novor The non-invasive and highly sensitive nature of EasyM™ makes it an ideal assay to assess MRD status as an efficacy endpoint for clinical trials of novel therapeutic drug... |
| 19.07.2022 | Alpaca Serum Antibodies Decoded with Rapid Novor’s De Novo Protein Sequencing Technology | Alpaca polyclonal nanobodies decoded REpAb® is well positioned to be a viable orthogonal antibody discovery platform to directly sequence those highly potent and highly developable antibodies. KITCHENER, Ontario (PRWEB) July 19, 2022 Rapid ... |
| 17.11.2021 | Rapid Novor, Inc. Ranked 296th Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™ | Protein de novo sequencing laboratory at Rapid Novor, Inc. At Rapid Novor, we aim to elevate human health by decoding immunity through next generation protein sequencing. KITCHENER, Ontario (PRWEB) November 17, 2021 Rapid Novor, Inc. today ... |
| 27.05.2021 | Rapid Novor First to Decode Polyclonal Antibodies Using Only Proteomics | RAPID NOVOR Mass Spectrometry Lab This is the first time in the world that animal polyclonal antibodies have been de novo sequenced successfully purely from protein. Past News ReleasesRSS KITCHENER, Ontario (PRWEB) May 27, 2021 Rapid Novor ... |
| 04.08.2020 | Today in funding: Medzy, Rapid Novor, Byta, VodaSafe | Four Canadian startups have announced fresh funding rounds to fuel their growth. Here’s the latest on who raised how much, from whom, and what they’ll be putting the new funds toward. Rapid Novor raises $6.6 million CAD Series A Kitchener-W... |